Aligned Bio

What Aligned Bio does

Aligned Bio AB is a privately held Swedish nanotechnology company, founded in 2019 and headquartered in Lund, that develops a patented nanowire sensing platform for ultra-sensitive single-molecule detection. The core technology uses semiconductor nanowires that function as nano-optical fibers, collecting and directionally emitting fluorescence from individual molecules bound to their surface. The company's patented Aerotaxy™ manufacturing methodology enables continuous, low-cost, scalable production and alignment of nanowires without traditional epitaxial growth, supporting applications across optical, electrochemical, and electrical sensor formats. Built on this platform, Aligned Bio offers a Next Generation DNA Sequencing platform (claiming 8X more genetic information at lower cost with read lengths up to 3,000 bases), the nFLIA nanowire fluorescence immunoassay for protein biomarker detection, and Single Molecule Biomarker Detection for oncology, infectious disease, and liquid biopsy use cases.

The company monetizes through a licensing and tailored platform development model, engaging enterprise customers in biotech, diagnostics, and life sciences via direct B2B sales, conference outreach, and strategic collaborations with academic partners including Lund University and Chalmers University of Technology. Aligned Bio holds 38 granted patents with additional filings pending, is supported by an EIC Accelerator Grant (NanoWi, no.190196128), and has raised approximately $8.1M across seed and grant rounds from investors including the European Innovation Council, SmiLe Inject Capital, Almi Invest, Faro Capital, Mist Ventures, LU Innovation, Stockholm Business Angels, and STOAF. The company operates in an expansion phase with active product development across sequencing and immunoassay verticals but no disclosed commercial revenue.

Name

Aligned Bio

Legal name

Aligned Bio AB

Website

https://alignedbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biosensor Technology

NAICS

Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

Keywords

• Nanowire biosensor platform
• Single molecule detection
• DNA sequencing technology
• Biomarker immunoassay tools
• Nanowaveguide diagnostics

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing: Flexible licensing of patented nanowire technology to customers. Licensing arrangements for use of proprietary technology in customer applications.
2. Tailored Platform Development: Custom platform development services for specific customer applications. Close collaboration for seamless integration of nanowire sensing technology.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Aligned Bio develops a customizable nanowire sensing platform for ultra-sensitive single molecule detection, enabling optical, electrochemical, and electrical sensors for DNA sequencing, biomarker detection, and immunoassay applications. The company offers flexible licensing of its patented technology alongside tailored platform development and close collaboration for seamless integration into customer applications. Core products include the Nanowire Sensing Platform, a Next Generation DNA Sequencing Platform, nFLIA (nanowire Fluorescence Immunoassay), and Single Molecule Biomarker Detection.

Product overview

Aligned Bio offers a modular nanowire sensing platform architecture with multiple application-specific products. The core is the Nanowire Sensing Platform, which provides the foundational technology for molecular detection. Built on this core are specialized applications including the Next Generation DNA Sequencing Platform for long-read sequencing, nFLIA for fluorescence immunoassays, and Single Molecule Biomarker Detection for ultra-sensitive disease biomarker identification. All products leverage the company's patented Aerotaxy™ nanowire production methodology and proprietary waveguide technology for signal amplification.

Differentiator

Problem solved

Functional benefit

Products and services

• Nanowire Sensing Platform A customizable nanowire-based sensing platform that enables ultra-sensitive molecular detection for optical, electrochemical, and electrical sensors. Features high surface-area-to-volume ratio and light-guiding efficiency for single molecule detection, with tailored platform development, flexible licensing of patented technology, and close collaboration for seamless integration. Targeted at biotech, diagnostics, and life sciences companies.
• Next Generation DNA Sequencing Platform A nanowire-based, intermediate to long-read DNA sequencing platform providing up to 8X the amount of genetic information in less time and cost. Uses proprietary nanowire waveguide technology that acts as single dye detectors, enabling breakthrough in sequencing cost, throughput, and read-length up to 2,000-3,000 base pairs. Targeted at sequencing and genomics companies.
• nFLIA (nanowire Fluorescence Immunoassay) A nanowire fluorescence immunoassay technology that leverages the company's nanowire waveguide platform for ultra-sensitive protein biomarker detection. Demonstrates significant sensitivity improvements over standard immunoassay protocols for advanced diagnostics. Targeted at IVD and immunoassay developers.
• Single Molecule Biomarker Detection Patented nanowire waveguide platform technology that improves sensitivity for targeted disease biomarkers by orders of magnitude over standard industry protocols. Enables next-generation immunoassays for advanced point-of-care diagnostics, liquid biopsies, and advanced multiplexing at picomolar or femtomolar detection levels.

Quantifiable outcome

• 8X more genetic information in less time and cost than industry leaders
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Lund UniversitycoreStrategic or Co-development PartnerCo-founders from Lund University. Scientific and corporate collaborators from Lund University's Physics and Immunology departments. Research foundation of the company originated from Lund University.
• Chalmers University of TechnologycoreStrategic or Co-development PartnerResearch collaboration with Chalmers University of Technology. Company co-founders include researchers from Chalmers. Technology developed based on research from both Lund University and Chalmers University of Technology.
• Well-known Disease Detection PartnersminorStrategic or Co-development PartnerCollaborating with well-known partners on disease detection projects. Specific partner names not disclosed in available sources.
• Medicon Valley AllianceminorOthersMember of Medicon Valley Alliance, a cross-border life science cluster organization in the Øresund region connecting Denmark and Sweden.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Sol Voltaics: Sol Voltaics, a Swedish nanowire technology company from which Aligned Bio's Nanowire Platforms Director Niklas Mårtensson came, develops Aerotaxy nanowire production for solar applications. It shares Aligned Bio's underlying nanowire manufacturing IP base and Scandinavian origin, making it a closely related regional peer even though end markets differ.

Direct peers

• Quanterix: Quanterix's Simoa platform performs single-molecule, ultra-sensitive protein biomarker detection at femtomolar levels—the same fundamental value proposition Aligned Bio targets with its nanowire waveguide-based Single Molecule Biomarker Detection and nFLIA immunoassay products. Both companies sell into IVD, pharma biomarker, and research customers using proprietary single-molecule sensing chemistries.
• Oxford Nanopore Technologies: Oxford Nanopore offers long-read, single-molecule DNA and RNA sequencing using a nanopore-based optical/electrical detection architecture, directly competing with Aligned Bio's nanowire-assisted single-molecule sequencing platform that claims up to 3,000-base read lengths. Both target sequencing service providers, clinical labs, and research customers seeking long-read genomic data.
• Pacific Biosciences: PacBio's SMRT sequencing (HiFi reads) is a leading long-read, single-molecule sequencing platform competing in the same application space as Aligned Bio's nanowire waveguide sequencing. Both companies use single-fluorophore detection on individual DNA molecules and pursue high-accuracy, intermediate-to-long reads for genomic and clinical applications.
• Quantum-Si: Quantum-Si's semiconductor-based single-molecule protein sequencing platform pursues ultra-sensitive proteomic detection on a chip, sharing Aligned Bio's thesis that semiconductor/solid-state nanowire structures can replace conventional immunoassays with single-molecule resolution. Both target pharma biomarker discovery and proteomics research customers.

Broad incumbents

• Illumina: Illumina dominates short-read sequencing and increasingly competes in long-read and proteomics-adjacent workflows. As the sequencing incumbent, it represents the enterprise customer and acquisition candidate that Aligned Bio's nanowire platform could either partner with or be acquired by to access scale.
• 10x Genomics: 10x Genomics offers single-cell and spatial omics platforms serving genomics and biomarker customers. Although it sells a different technology stack, it represents the broad incumbent that Aligned Bio's single-molecule biomarker platform would compete with in advanced multiplexing applications.

Emerging players

• Element Biosciences: Element is an emerging sequencing platform company pursuing cost- and accuracy-advantaged short-read sequencing; it competes with Aligned Bio for next-generation sequencing customers seeking differentiated technology platforms. Both challenge incumbents with novel detection chemistries.
• Singular Genomics: Singular Genomics offers novel sequencing and multiomics platforms targeted at benchtop use cases, overlapping with Aligned Bio's pursuit of lower-cost, more accessible sequencing and biomarker detection for translational and clinical customers.
• NanoString Technologies: NanoString's nCounter and spatial omics platforms target high-multiplex biomarker measurement in research and translational markets—the same customer need Aligned Bio's high-sensitivity nanowire immunoassays address, particularly for advanced multiplexing and spatial pathology workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aligndsystems

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aligned Bio